Document Detail

The impact of treatment with hylan G-F 20 on progression to total hip arthroplasty in patients with symptomatic hip OA: A retrospective study.
MedLine Citation:
PMID:  22126424     Owner:  NLM     Status:  Publisher    
Abstract Introduction: There is scarce data available on intra-articular hyaluronan's ability to modify the progression of osteoarthritis (OA). Objective: The purpose of this retrospective, pilot study was to assess the impact of treatment with hylan G-F 20 on progression to total hip replacement (THR) in patients with symptomatic hip OA. Research Design and Methods: The records of patients presenting with symptomatic hip OA and treated with hylan G-F 20 were analysed. Endpoints were the number of THR's performed and the survival time (in months) between commencement of treatment and THR, if performed. Endpoints were evaluated for the entire study population and for those sub-groups of patients which were, or were not, defined as candidates for THR prior to intra-articular treatment. Predictive factors of progression to THR were also assessed. Results: 850 patients' records were evaluated and 224 patients' data were included in the study and evaluated. 84 patients (37.5%) progressed to THR. 206 patients (92.0%) achieved 12 months survival, 170 patients (75.9%) achieved 24 months survival, and 69 patients (30.8%) achieved 5 years survival. Mean survival time was 36 months. Classification as a THR candidate, Lequesne score, ultrasound pattern and the presence of diabetes were predictive factors for progression to THR. Conclusions: These results suggest that hylan G-F 20 could be included in the management of symptomatic hip OA before recommendation for THR, particularly in patients presenting with milder symptoms, or in patients where, due to comorbidities or personal choice, THR is not a feasible option. Limitations of this study include the retrospective study design and the lack of a control group to determine any placebo effect of hylan G-F 20. Further prospective studies are therefore needed to corroborate these results.
A Migliore; E Bizzi; U Massafra; A Bella; P Piscitelli; B Laganà; S Tormenta
Related Documents :
21682834 - A randomized, parallel group, double-blind, multicentre study comparing the efficacy an...
25376324 - Cutting peripherally inserted central catheters may lead to increased rates of catheter...
21909034 - Evaluation of shoulder balance through growing rod intervention for early-onset scoliosis.
21688044 - Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in th...
23086134 - What is the success of drug treatment in urge urinary incontinence? what should be meas...
24783914 - Treatment of rheumatoid arthritis with biologic dmards (rituximab and etanercept).
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-11-30
Journal Detail:
Title:  Current medical research and opinion     Volume:  -     ISSN:  1473-4877     ISO Abbreviation:  -     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Rheumatology, San Pietro Fatebenefratelli Hospital , Rome , Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.
Next Document:  Risk factors for invasive fungal disease in critically ill adult patients: a systematic review.